Q-omics provides the consensus-scored MYMK profile across patient tissues and cancer cell-line models. MYMK expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MYMK is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, MYMK RNA expression shows 9,202 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight HNSC, and KIRC as cancer lineages where MYMK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYMK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYMK survival associations across molecular data types. MYMK RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYMK RNA expression–survival associations across cancer types. High MYMK expression shows unfavorable associations in HNSC, SARC, ACC and UCEC, but favorable associations in UCS and KIRP. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for MYMK RNA expression.
This table summarizes MYMK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MYMK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYMK shows lower tumor expression in KIRC, KIRP, KICH and LUSC and higher tumor expression in HNSC and COAD. The KIRC box plot shows higher MYMK RNA expression in normal versus tumor tissue (log2 FC = −0.918, t-test p < 0.001).
This table shows molecular features associated with MYMK in patient tissues and cancer cell lines. In patient samples, MYMK shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYMK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
